Pluri Inc. reported a revenue of $1.016 million for the fiscal year ending June 30, 2026, a decrease from $1.336 million in the previous year. The decline in revenue was attributed to a lower volume of project activity in its Contract Development and Manufacturing Organization (CDMO) services and proof-of-concept collaborations in the FoodTech sector. The company's cost of revenues also decreased to $563,000 from $682,000, reflecting the reduced project activity. However, Pluri's net loss increased to $25.369 million from $23.250 million, primarily due to higher research and development expenses, which rose by 17% to $15.092 million, and increased general and administrative costs.
In terms of strategic developments, Pluri has made significant organizational changes, including the acquisition of approximately 79% of Kokomodo, an Israeli agfood startup, in April 2025. This acquisition is expected to enhance Pluri's capabilities in cellular agriculture technology. Additionally, the company established a new subsidiary, Coffeesai, in March 2024, focusing on developing cultivated coffee products. Pluri also launched its Cellav subsidiary in November 2025, which is dedicated to regenerative aesthetics and wellness products. These strategic moves are part of Pluri's broader goal to leverage its proprietary 3D cell expansion platform across various sectors, including human health and food technology.
Operationally, Pluri's employee headcount as of June 30, 2026, stood at 113, comprising 92 full-time and 21 part-time employees. The company has been actively engaging in collaborations, including a partnership with Bar-Ilan University for the development of PLX cells for treating cocaine addiction and a collaboration with Hemafund for the advancement of PLX-R18 cell therapy. Pluri's CDMO business has also entered into several commercial agreements, indicating a growing client base and operational engagement.
Looking ahead, Pluri faces substantial liquidity challenges, with a working capital deficit of $23.989 million as of June 30, 2026. The company has indicated that it has sufficient resources to meet its obligations for less than three months from the issuance of its financial statements. Management is exploring various options to secure additional capital, including potential licensing agreements and strategic partnerships. The company is also in discussions regarding the resolution of its outstanding loan with the European Investment Bank, which became due on June 1, 2026. The outcome of these discussions and the ability to secure further funding will be critical for Pluri's ongoing operations and future growth.
About Pluri Inc.
Pluri Inc. is a biotechnology company specializing in proprietary 3D cell expansion technology for scalable solutions across healthcare, food, and agriculture. Its core activities include developing cell therapies, regenerative medicine, cultivated food products, and contract manufacturing services. The company leverages its innovative platform for cell-based therapeutics, food tech, and AgTech, serving global markets with a focus on sustainability, cost-efficiency, and advanced bioprocessing.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov